Literature DB >> 25593125

Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia.

Xianwu Li1, Kathleen S Montine2, C Dirk Keene2, Thomas J Montine2.   

Abstract

Several lines of evidence support immune response in brain as a mechanism of injury in Alzheimer disease (AD). Moreover, immune activation is heightened in apolipoprotein E (APOE) ε4 carriers; inhibitors of prostaglandin (PG) synthesis show a partially protective effect on AD risk from APOE ε4; and genetic variants in triggering receptor expressed on myeloid cells 2 (TREM2) are a rare but potent risk for AD. We tested the hypothesis that APOE ε4 inheritance modulates both the PGE2 pathway and TREM2 expression using primary murine microglia from targeted replacement (TR) APOE3/3 and APOE4/4 mice. Microglial cyclooxygenase-2, microsomal PGE synthase, and PGE2 expression were increased 2- to 25-fold in both genotypes by TLR activators; however, this induction was significantly (P < 0.01) greater in TR APOE4/4 microglia with TLR3 and TLR4 activators. Microglial TREM2 expression was reduced approximately 85% by all TLR activators; this reduction was approximately one-third greater in microglia from TR APOE4/4 mice. Importantly, both receptor-associated protein and a nuclear factor κ-light-chain-enhancer inhibitor blocked TR APOE4/4-dependent effects on the PGE2 pathway but not on TREM2 expression. These data demonstrate complementary, but mechanistically distinct, regulation of pro- and anti-inflammatory mediators in TR APOE4/4 murine microglia that yields a more proinflammatory state than with TR APOE3/3. © FASEB.

Entities:  

Keywords:  Alzheimer disease; PGE2; apolipoprotein E genotype; brain immunity; neuroinflammation

Mesh:

Substances:

Year:  2015        PMID: 25593125      PMCID: PMC4415020          DOI: 10.1096/fj.14-262683

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  56 in total

1.  Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12.

Authors:  Jessica A Hamerman; Jessica R Jarjoura; Mary Beth Humphrey; Mary C Nakamura; William E Seaman; Lewis L Lanier
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

2.  Cutting edge: TREM-2 attenuates macrophage activation.

Authors:  Isaiah R Turnbull; Susan Gilfillan; Marina Cella; Taiki Aoshi; Mark Miller; Laura Piccio; Maristela Hernandez; Marco Colonna
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

Review 3.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

Review 4.  Structure, expression pattern and biological activity of molecular complex TREM-2/DAP12.

Authors:  Agnieszka Paradowska-Gorycka; Monika Jurkowska
Journal:  Hum Immunol       Date:  2013-02-28       Impact factor: 2.850

5.  Variant of TREM2 associated with the risk of Alzheimer's disease.

Authors:  Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

6.  APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response.

Authors:  John R Lynch; Wen Tang; Haichen Wang; Michael P Vitek; Ellen R Bennett; Patrick M Sullivan; David S Warner; Daniel T Laskowitz
Journal:  J Biol Chem       Date:  2003-09-24       Impact factor: 5.157

7.  Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.

Authors:  T Wisniewski; E M Castaño; A Golabek; T Vogel; B Frangione
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

8.  Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK.

Authors:  Izumi Maezawa; Mary Nivison; Kathleen S Montine; Nobuyo Maeda; Thomas J Montine
Journal:  FASEB J       Date:  2006-02-15       Impact factor: 5.191

9.  TREM2 variants in Alzheimer's disease.

Authors:  Rita Guerreiro; Aleksandra Wojtas; Jose Bras; Minerva Carrasquillo; Ekaterina Rogaeva; Elisa Majounie; Carlos Cruchaga; Celeste Sassi; John S K Kauwe; Steven Younkin; Lilinaz Hazrati; John Collinge; Jennifer Pocock; Tammaryn Lashley; Julie Williams; Jean-Charles Lambert; Philippe Amouyel; Alison Goate; Rosa Rademakers; Kevin Morgan; John Powell; Peter St George-Hyslop; Andrew Singleton; John Hardy
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

10.  Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial activation.

Authors:  Eiron Cudaback; Xianwu Li; Yue Yang; Thomas Yoo; Kathleen S Montine; Suzanne Craft; Thomas J Montine; Christopher Dirk Keene
Journal:  J Neuroinflammation       Date:  2012-08-10       Impact factor: 8.322

View more
  24 in total

Review 1.  Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Authors:  Tien-Phat V Huynh; Albert A Davis; Jason D Ulrich; David M Holtzman
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

2.  Human Striatal Dopaminergic and Regional Serotonergic Synaptic Degeneration with Lewy Body Disease and Inheritance of APOE ε4.

Authors:  Nadia Postupna; Caitlin S Latimer; Eric B Larson; Emily Sherfield; Julie Paladin; Carol A Shively; Matthew J Jorgensen; Rachel N Andrews; Jay R Kaplan; Paul K Crane; Kathleen S Montine; Suzanne Craft; C Dirk Keene; Thomas J Montine
Journal:  Am J Pathol       Date:  2017-02-16       Impact factor: 4.307

Review 3.  Microglia-Mediated Neuroprotection, TREM2, and Alzheimer's Disease: Evidence From Optical Imaging.

Authors:  Carlo Condello; Peng Yuan; Jaime Grutzendler
Journal:  Biol Psychiatry       Date:  2017-10-14       Impact factor: 13.382

Review 4.  Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease.

Authors:  Nathaniel S Woodling; Katrin I Andreasson
Journal:  ACS Chem Neurosci       Date:  2016-04-04       Impact factor: 4.418

Review 5.  Microglial malfunction: the third rail in the development of Alzheimer's disease.

Authors:  Siddhita D Mhatre; Connie A Tsai; Amanda J Rubin; Michelle L James; Katrin I Andreasson
Journal:  Trends Neurosci       Date:  2015-10       Impact factor: 13.837

6.  Characterization of cognitive impairments and neurotransmitter changes in a novel transgenic mouse lacking Slc10a4.

Authors:  E J Melief; J T Gibbs; X Li; R G Morgan; C D Keene; T J Montine; R D Palmiter; M Darvas
Journal:  Neuroscience       Date:  2016-03-19       Impact factor: 3.590

7.  Poly(I:C) increases the expression of mPGES-1 and COX-2 in rat primary microglia.

Authors:  Antonio Carlos Pinheiro de Oliveira; Nizar M Yousif; Harsharan Singh Bhatia; Julia Hermanek; Michael Huell; Bernd L Fiebich
Journal:  J Neuroinflammation       Date:  2016-01-18       Impact factor: 8.322

Review 8.  Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease.

Authors:  Fan Liao; Hyejin Yoon; Jungsu Kim
Journal:  Curr Opin Lipidol       Date:  2017-02       Impact factor: 4.776

Review 9.  Insight into the Molecular Imaging of Alzheimer's Disease.

Authors:  Abishek Arora; Neeta Bhagat
Journal:  Int J Biomed Imaging       Date:  2016-01-10

Review 10.  APOE genotype and stress response - a mini review.

Authors:  Janina Dose; Patricia Huebbe; Almut Nebel; Gerald Rimbach
Journal:  Lipids Health Dis       Date:  2016-07-25       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.